SYDNEY, AUSTRALIA // Laila Chamaa is Business Unit Director for the Neuroscience Franchise at Janssen a leading research based pharmaceutical company within the Johnson and Johnson family of companies. Janssen embraces research and science – bringing innovative ideas, products and services to advance the health and well-being of people with chronic illnesses like schizophrenia, ADHD and severe pain.

Caring for patients is at the heart of the Neuroscience vision which is dedicated to helping people living with neuropsychiatric disorders live a more fulfilling and contributing life. Over the last couple of years, Laila has led the drive to develop integrated solutions for people living with schizophrenia, to help them and their carers navigate an increasingly complex health system. These solutions include nurse care coordination, telephone support and reminder services as well as education programs for a multitude of providers engaged in the delivery of care.

Ms Chamaa has had over 17 years of experience in the pharmaceutical sector and during this time, she has worked across a number of commercial and leadership roles spanning different therapeutic areas and geographies including Australia, Asia Pacific and the US.

Ms Chamaa holds a Bachelor of Science degree from the University of Sydney, Australia and an MBA from the University of Technology, Sydney.